Heme oxygenase-1 modulation: A potential therapeutic target for COVID-19 and associated complications
| Autor: | Devendra Singh, Kh. Reeta, Himika Wasan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
ARDS Type-1 IFNs Coronavirus disease 2019 (COVID-19) Inflammation HO-1 promoter polymorphism Heme Antiviral Agents Polymorphism Single Nucleotide Biochemistry Hypothesis Paper 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Fibrinolytic Agents Coagulopathy Physiology (medical) medicine Humans Antiviral activity SARS-CoV-2 business.industry COVID-19 Disseminated Intravascular Coagulation medicine.disease COVID-19 Drug Treatment Heme oxygenase 030104 developmental biology Viral replication chemistry Novel virus Interferon Type I Immunology medicine.symptom business Heme Oxygenase-1 030217 neurology & neurosurgery |
| Zdroj: | Free Radical Biology and Medicine Free Radical Biology & Medicine |
| ISSN: | 0891-5849 |
| DOI: | 10.1016/j.freeradbiomed.2020.10.016 |
| Popis: | Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to infect hundred thousands of people every day worldwide. Since it is a novel virus, research continues to update the possible therapeutic targets when new evidence regarding COVID-19 are gathered. This article presents an evidence-based hypothesis that activating the heme oxygenase-1 (HO-1) pathway is a potential target for COVID-19. Interferons (IFNs) have broad-spectrum antiviral activity including against SARS-CoV-2. Induction of HO-1 and increase in the heme catabolism end-product confer antiviral activity. IFN activation-results in inhibition of viral replication in various viral infections. COVID-19 induces inflammation as well as acute respiratory distress syndrome (ARDS), and coagulopathies are now known major causes of mortality. A protective role of HO-1 induction in inflammation, inflammation-induced coagulation, and ARDS has been reported. Based on an association of HO-1 promoter polymorphisms and disease severity, we propose an evaluation of the status of these polymorphisms in COVID-19 patients who become severely ill. If an association is established, it might be helpful in identifying patients at high risk. Hence, we hypothesize that HO-1 pathway activation could be a therapeutic strategy against COVID-19 and associated complications. Graphical abstract Image 1 Highlights • COVID-19 causes significant mortality and needs urgent treatment strategies. • SARS-CoV-2 inhibits interferons (IFN) and increased IFNs suppresses its replication. • Heme oxygenase-1 (HO-1) inducers suppress viral replication by increasing IFNs. • HO-1 promoter polymorphisms modulate disease severity, which may be true in COVID-19. • Inflammation and coagulopathies seen in COVID-19 can be controlled by inducing HO-1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect